IMB071703 / Immune Ark - LARVOL DELTA

A phase Ia, dose-escalation study of IMB071703 injection in patients (pts) with recurrent or metastatic, advanced solid tumors. (ASCO 2024) - "We confirmed the expansion of antigen-specific T cells in various mouse models and potent tumor regression administrated by IMB071703 alone or in combination with gemcitabine in vivo, concomitant with improved tumor-reactive T-cell infiltration. IMB071703 Showed a good safety profile at the dose levels of 0. 05 mg/kg, 0. 15 mg/kg, and 0."

Clinical • IO biomarker • Metastases • Fatigue • Hepatology • Oncology • Pain • Solid Tumor • CD40LG • CD8 • PD-1

Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=93 | Recruiting | Sponsor: Beijng Immunoah Pharma Tech Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor